Medication | Cohort (n=253) |
Anticoagulation (%) | |
No anticoagulant medications | 58.5 |
Warfarin | 20.2 |
Antiplatelet | 13.8 |
Novel anticoagulant | 0.8 |
Warfarin and antiplatelet | 2.0 |
Dual antiplatelet | 0.4 |
Novel anticoagulant and aspirin | 0.4 |
Previous warfarin | 2.4 |
Previous aspirin | 1.6 |
Digoxin (%) | 11.9 |
Calcium channel blockers (%) | 2.0 |
Diuretics (%) | 32.3 |
Exposure to advanced therapy (%) | 71.9 |
Current number of advanced therapies (%) | |
0 | 30.8 |
1 | 49.4 |
2 | 19.4 |
3 | 0.4 |
Combination therapy (n=50) | % (number of subjects) |
Bosentan and sildenafil | 68 (34/50) |
Macitentan and sildenafil | 26 (13/50) |
Macitentan and tadalafil | 2 (1/50) |
Sildenafil and prostacyclins | 2 (1/50) |
Sildenafil, macitentan and prostacyclins | 2 (1/50) |
Previous warfarin: subjects treated with warfarin during the study but ceased before time of last review; previous aspirin: subjects treated with aspirin during the study but therapy ceased before time of last review; combination therapy: the subset of patients on more than one advanced therapy (50 subjects). Data available in 100% of subjects for each variable.